TheraRadar
← Back
Data updated: May 24, 2026

TANVEX BIOPHARMA USA INC

Biotech

TANVEX BIOPHARMA USA INC is a biotechnology company focused on Oncology.

2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Oncology 100%
1 drugs Phase 3: 2

Top Competitors

Companies with the most overlap in therapeutic areas and drug targets. Based on approved drugs and pipeline focus.

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

2
Phase 3
0
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • NYPOZI leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling